Sunscreen compositions containing imine analogues of ketone-containing sunscreens
Sunscreen compositions with imine analogs of ketone-containing UV filters address the need for FDA-approved broad-spectrum protection by enhancing UV protection to the visible range, ensuring water-resistance, and reducing skin penetration, thereby improving safety and efficacy.
Patent Information
- Application Number
- JP2024527351
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-11
- Filing Date
- 2022-11-09
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for new sunscreen compositions that utilize FDA-approved UV filters that can match or exceed the effectiveness of triazine-containing UV filters, which are currently not approved in the United States, and provide broad-spectrum protection including the visible light range, are water-resistant, and minimize skin penetration.
The development of sunscreen compositions comprising ketone-containing UV filters that react with primary or secondary amines to form imine analogs, which extend UV protection to the visible range, are water-resistant, and reduce skin penetration, using imine analogs of ketone-containing UV filters such as avobenzone, diethylaminohydroxybenzoylhexylbenzoate, and sulisobenzone, and modifying these with transglutaminase or lysyl oxidase to bind to targets like collagen and elastin.
The imine analogs provide enhanced UV protection across the UVA-1, UVA-2, and UVB regions, are water-resistant, and minimize skin penetration, offering improved safety and efficacy compared to existing sunscreens.
Smart Images

Figure 2024543376000018 
Figure 2024543376000019 
Figure 2024543376000020
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Patent Application Publication No. 17 / 524,222, filed November 11, 2021, which is incorporated by reference in its entirety.
[0002] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH This invention was made in part with Government support under Grant No. 2026057 awarded by the National Science Foundation. The Government has certain rights in this invention.
[0003] Incorporation by Reference The sequence listing provided in the file entitled SequenceListing.txt, created on November 7, 2022 and submitted herewith, having a size of 24,235 bytes, is incorporated by reference in its entirety.
[0004] Field The present invention relates to sunscreen compositions comprising imine analogues of ketone-containing UV filters that have at least one property selected from the group consisting of: a) being able to extend UV protection into the visible range at or above 400 nm, b) being water resistant, and / or c) preventing or reducing skin penetration. [Background technology]
[0005] Ultraviolet (UV) filters are compounds, mixtures, or materials that block or absorb UV light. One of the main applications of UV filters is their use as sunscreens to protect the skin from sunburn and other sun / UV-related damage. Because excess UV rays can cause sunburn, photoaging, and skin cancer, care products such as sunscreens usually include a classification for the specific wavelengths they filter. UV classifications include UVA (320-400 nm), UVB (290-320 nm), and UVC (200-280 nm). Broad-spectrum sunscreens protect against both UVA and UVB rays.
[0006] UV-absorbing compounds are used in sunscreens as well as other personal care products, such as lipstick, shampoos, hairsprays, body washes, and insect repellents. Chemical filters protect against UV rays by absorbing, reflecting, or scattering the radiation. Reflection and scattering are accomplished by inorganic UV filters, such as titanium dioxide and zinc oxide. Absorption, primarily of UVB, is accomplished by organic UV filters.
[0007] The European Union determines broad spectrum protection by the ratio of UVA to UVB protection, and requires that one-third of the Sun Protection Factor (SPF) number is UVA protection. Currently, there are eight EU-approved UVA filters used in European sunscreens. Some of the EU-approved UVA filters are triazine-containing UV filters. They also provide some UVB protection. Unfortunately, such compounds have not yet been approved by the FDA for use in the United States, and it is unclear when such approval will occur.
[0008] Therefore, there remains a need to develop new sunscreens that use FDA-approved UV filters that match or potentially even exceed the effectiveness of these triazine-containing UV filters. Summary of the Invention
[0009] In a first embodiment, a sunscreen composition is disclosed comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter and the at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter, said imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection to 400 nm or above the visible range; b) being water resistant; and / or c) preventing or reducing skin penetration.
[0010] In a second embodiment, the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate, sulisobenzone, and oxybenzone.
[0011] In a third embodiment, the imine analog form of the ketone-containing UV filter may be further modified to react with transglutaminase or any variant thereof and / or lysyl oxidase to provide a substrate capable of binding the sunscreen composition to a target of interest.
[0012] In a fourth embodiment, a sunscreen active ingredient is disclosed, comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter and the at least one primary or secondary amine react to form an imine analogue of the ketone-containing UV filter, and the imine analogue has at least one property selected from the group consisting of a) UV protection can be extended to 400 nm or more in the visible region, b) water resistance, and / or c) prevents or reduces skin penetration.Preferably, the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate, sulisobenzone, and oxybenzone.
[0013] In a fifth embodiment, the imine analogue form of the ketone-containing UV filter of the sunscreen active is further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and / or lysyl oxidase to bind said sunscreen active to a target of interest.
[0014] In a sixth embodiment, a cosmetic or pharmaceutical preparation is disclosed comprising at least one of the sunscreen compositions or sunscreen actives described herein and a cosmetically or pharma- ceutically acceptable carrier. [Brief description of the drawings]
[0015] [Figure 1] FIG. 1 shows the UV / Vis spectral characteristics of imine-1, imine-2, and imine-3 in acetonitrile compared to oxybenzone. [Diagram 2] FIG. 1 shows the UV / Vis spectral characteristics of carbamate-1 in acetonitrile compared to oxybenzone. [Diagram 3] FIG. 1 shows the UV / Vis spectral characteristics of imine-4, imine-5, and N-Boc-imine-6 in acetonitrile compared to oxybenzone. [Figure 4] FIG. 1 shows the UV / Vis spectral characteristics of N-Boc-imine-6 in ethanol. [Diagram 5] FIG. 1 shows UV / Vis spectral characteristics of imine-7 and N-Boc-imine-7 in acetonitrile compared to avobenzone. [Figure 6] FIG. 1 shows the UV / Vis spectral characteristics of N-Boc-imine-8 and imine-8 in ethanol compared to approximately equal concentrations of sulisobenzone. [Figure 7] FIG. 1 shows the UV / Vis spectral characteristics of imine-10 in ethanol. [Figure 8]FIG. 1 depicts the structures of avobenzone, oxybenzone, sulisobenzone, DHHB, and the imines described in the Examples below, along with their estimated LogP values as determined by ChemDraw. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] A brief description of the sequence The sequences below comply with 37 CFR §§ 1.821-1.825 ("Requirements for Patent Applications Containing Nucleotide Sequences and / or Amino Acid Sequence Disclosure-the Sequence Rules"), World Intellectual Property Organization (WIPO) Standard ST.25 (2009) and Rules 5.2 and 49.5(a-bis) of the European Patent Convention (EPC) and Patent Cooperation Treaty (PCT), as well as the sequence listing requirements of Section 208 and Annex C of the Administrative Instructions. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 CFR § 1.822.
[0017] SEQ ID NO: 1 corresponds to the amino acid sequence of the wild-type transglutaminase (Tgase) sequence of Streptomyces mobaraensis.
[0018] SEQ ID NO:2 corresponds to a variant of the sequence of SEQ ID NO:1, which variant has a triple mutation (N282E, H289I, and S299K) compared to SEQ ID NO:1.
[0019] SEQ ID NO:3 corresponds to a variant of SEQ ID NO:1, which has quadruple mutations (N282K, G283A, S284P, and S299V) compared to SEQ ID NO:1.
[0020] SEQ ID NO:4 corresponds to a variant of SEQ ID NO:1, which has a double mutation (S199A and S299A) compared to SEQ ID NO:1.
[0021] SEQ ID NO:5 corresponds to a variant of SEQ ID NO:1, which has a double mutation (S199A and S299V) compared to SEQ ID NO:1.
[0022] SEQ ID NO:6 corresponds to a variant of SEQ ID NO:1, which has a triple mutation (S2P, S199G and S299V) compared to SEQ ID NO:1.
[0023] SEQ ID NO:7 corresponds to a variant of SEQ ID NO:1, which has a single mutation (S2P) compared to SEQ ID NO:1.
[0024] SEQ ID NO:8 corresponds to SEQ ID NO:1 with a polyhistidine tag, ie wild type Tgase with a polyhistidine tag.
[0025] All patents, patent applications, and publications cited herein are incorporated by reference in their entirety.
[0026] Unless the context clearly dictates otherwise, words using the singular include the plural and vice versa.
[0027] Throughout this application, various embodiments may be presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the embodiments described herein. Thus, the description of a range should be considered to specifically disclose all possible subranges as well as individual numerical values within that range. For example, the description of a range such as 1-6 should be considered to have subranges such as 1-2, 1-3, 1-4 and 1-5, 2-3, 2-4, 2-5, 2-6, 3-4, 3-5, 3-6, and individual numbers within that range, for example, 1, 2, 3, 4, 5 and 6. This applies regardless of the breadth of the range.
[0028] In this disclosure, a number of terms and abbreviations are used. Unless otherwise stated, the following definitions apply.
[0029] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. For example, the term "a compound" or "at least one compound" can include multiple compounds, including mixtures thereof. The terms "a," "an," "the," "one or more," and "at least one," for example, can be used interchangeably herein.
[0030] The term "about" as used herein can allow for some variability in values or ranges, for example, within 10%, within 5%, or within 1% of a stated value or the limits of a stated range.
[0031] The term "amino acid" refers to the basic chemical structural unit of a protein, peptide, or polypeptide. The following abbreviations used herein to identify specific amino acids can be found in Table 1.
[0032] [Table 1]
[0033] The terms "and / or" and "or" are used interchangeably herein to refer to a particular disclosure of two specified features or components with or without the other. Thus, the term "and / or" used in phrases such as "A and / or B" is intended to include "A and B," "A or B," "A" (single), and "B" (single). Similarly, the term "and / or" used in phrases such as "A, B, and / or C" is intended to include each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B, or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0034] The term "avobenzone" refers to the compound C, which absorbs UVA rays and is used as an ingredient in sunscreens. 20 H 22 O3 (CAS Registry Number 70356-09-1). UVA rays are the type of UV light that causes skin cancer and skin aging. However, Avobenzone breaks down in sunlight, so it is usually combined with other ingredients to be effective. Avobenzone is approved by the FDA in concentrations up to 3%. Avobenzone is sold under the trademark Parsol®.
[0035] The term "composition" refers to a combination of two or more substances or compounds.
[0036] The terms "comprises," "comprising," "includes," "including," "having," and conjugations thereof, are used interchangeably and mean "including, but not limited to." Whenever an embodiment is described herein with the word "comprising," it is understood that other similar embodiments described with the words "consisting of" and / or "consisting essentially of" are also provided.
[0037] The term "consisting of" means "including and limited to."
[0038] The term "consisting essentially of" means the specified materials of a composition, or the specified step of a process, and any additional materials or steps that do not materially affect the basic characteristics of the material or process.
[0039] As used herein with reference to amino acid residue positions, "corresponding to" or "corresponds to" or "corresponding to" or "corresponds" refers to the amino acid residue at the recited position in a protein or peptide, or amino acid residues that are similar, homologous, or equivalent to the recited residue in a protein or peptide. As used herein, a "corresponding region" generally refers to an analogous position in a related or reference protein.
[0040] Those skilled in the art will understand that modifications of the amino acid sequences disclosed herein may be made while retaining the functionality associated with the disclosed amino acid sequences. For example, it is well known in the art that genetic alterations that result in the production of a chemically equivalent amino acid at a given site but do not affect the functional properties of the encoded protein are common.
[0041] The term "cosmetics" refers to most personal care, skin care, makeup and cosmetics. A cosmetic is any substance or preparation intended to be placed in contact with any part of the human body for the purposes of altering body odor, altering the appearance of the body, cleansing the body, keeping the body in good condition, scenting the body, and / or protecting the body. Cosmetics include, but are not limited to, soaps, shampoos and conditioners, moisturizers, bath bombs, hair dyes, perfumes, lipsticks, mascaras, nail polish, deodorants and many other products. A "cosmetic preparation" is in a ready-to-use form.
[0042] The term "DHHB" has the molecular formula C 24 H 31 It refers to diethylamino hydroxybenzoyl hexyl benzoate with NO4 (CAS Registry Number 302776-68-7). DHHB is a UV filter with a high absorption in the UV-A range. It was approved in Europe in 2005.
[0043] The term "derived from" encompasses the terms "resulting from," "obtained from," "obtainable from," "isolated from," "purified from," and "made from," and generally indicates that one specified material has characteristics that can be found in, or described with reference to, another specified material.
[0044] The term "imine" refers to any of a class of organic nitrogen compounds having the general formula R2C=NR, which are tautomeric with "enamines". Tautomers are structural isomers of compounds that readily interconvert. Thus, the term "imine" as used herein refers to both "imines" and their corresponding structural isomers, "enamines". The terms "structural isomer" and "tautomer" are used interchangeably herein.
[0045] As used herein, the terms "isolated," "purified," "separated," and "recovered" refer to a material (e.g., a protein, a nucleic acid, or a cell) that has been removed from at least one component that is naturally associated with it. For example, these terms can refer to a material that is substantially or essentially free of components that normally accompany it in its native state, e.g., as found in an intact biological system. Isolated nucleic acid molecules include nucleic acid molecules contained in cells that normally express the nucleic acid molecule, but where the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0046] The term "ketone-containing UV filter" refers to a) any compound or mixture of compounds that contains a carbonyl moiety in which a carbon atom is covalently bonded to an oxygen atom as indicated by the structure: R2C=O, where R can be a variety of carbon-containing substituents, i.e., R is not a hydrogen atom, and b) such a compound or mixture of compounds is also capable of blocking or absorbing UV light.
[0047] The term "lysyl oxidase" ("LOX") (also known as protein-lysine 6-oxidase) refers to a copper-dependent enzyme that catalyzes the formation of aldehydes from lysine residues in collagen and elastin precursors. These aldehydes are highly reactive and undergo spontaneous chemical reactions with aldehyde residues from other lysyl oxidases or with unmodified lysine residues. The result is cross-linking of collagen and elastin. LOX proteins have been identified in animals, other eukaryotes, as well as bacteria and archaea (reviewed in Grau-Bove, et al. (2015) Scientific Reports 5: Article number: 10568).
[0048] The term "mutation" as used herein refers to changes, including but not limited to substitutions, insertions, and deletions (including truncations), that are introduced into a parent sequence, thereby resulting in a "mutant." The results of a mutation include, but are not limited to, the production of a new feature, characteristic, function, phenotype, or trait not found in the protein encoded by the parent sequence.
[0049] "Optional" or "optionally" means that the subsequently described event, circumstance, or material may or may not occur, be present, or be absent, and the description includes instances where the event, circumstance, or material occurs or is present, as well as instances where it does not occur or is absent.
[0050] The term "oxybenzone" has the molecular formula C 14 H 12 O3 (CAS Registry Number 131-57-7). It is a benzophenone derivative used as a sunscreen. It is approved by the FDA in concentrations up to 6%. It absorbs UVB rays and some UVA rays.
[0051] The terms "peptide", "protein" and "polypeptide" are used interchangeably herein and refer to a polymer of amino acids linked together by peptide bonds. A "protein" or "polypeptide" comprises a polymeric sequence of amino acid residues. The one-letter and three-letter codes for amino acids defined according to the IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN) are used throughout this disclosure. The single letter X refers to any of the 20 amino acids. It is also understood that a polypeptide can be coded for by two or more nucleotide sequences due to the degeneracy of the genetic code. Mutations can be named by the one-letter code of the parent amino acid followed by the position number followed by the one-letter code of the variant amino acid. For example, mutating glycine (G) at position 87 to serine (S) is represented as "G087S" or "G87S". When describing a modification, a position followed by multiple amino acids listed in parentheses indicates a list of substitutions at that position with any of the listed amino acids. For example, 6(L,I) means that position 6 can be substituted with leucine or isoleucine. In some cases, a slash ( / ) is used in the sequence to define a substitution, e.g., F / V indicates that the position can have a phenylalanine or a valine at that position.
[0052] The term "pharmaceutical preparation" refers to a drug presented in its finished dosage form, i.e., ready for use, intended for human or veterinary use.
[0053] The term "primary amine" refers to an organic derivative of ammonia in which one of the hydrogen atoms is replaced by, for example, but not limited to, unsubstituted or substituted alkyl, cyclic alkyl, or aromatic / heteroaromatic groups.
[0054] The term "secondary amine" refers to an organic derivative of ammonia in which two of the hydrogen atoms have been replaced by, for example, but not limited to, unsubstituted or substituted alkyl and / or aromatic / heteroaromatic groups.
[0055] The term "sulisobenzone" has the molecular formula C 14 H 12 It refers to 5-benzoyl-4-hydroxy-2-methoxybenzenesulfonic acid, which has the CAS Registry Number O6S (4065-45-6). It is approved by the FDA in concentrations up to 10%. It works to filter out UVA and UVB rays. It is used as a UV filter ingredient in sunscreens and other personal care products.
[0056] The terms "sunscreen" and "sunscreen composition" are used interchangeably herein and refer to any compound, substance, mixture, or material that can block or absorb UV radiation, which can be considered a photoprotective topical agent.
[0057] The term "sunscreen active" refers to a compound or portion of a substance that produces a desired chemical or biological effect, in this case involving blocking, reflecting or absorbing UVA and UVB radiation.
[0058] The term "target of interest" refers to any exogenous protein or peptide, such as a dermatologically relevant protein, or any part of the human or animal body, suitable for binding to the imine form of any ketone-containing UV filter modified to act as a substrate for Tgase or any variant thereof.Tgase or any variant thereof then catalyzes the reaction in which the modified imine is conjugated / bound to the relevant part of the human body, i.e., the target of interest.For example, the target of interest can include, but is not limited to, glutamine-glycine, collagen, keratin and / or elastin.
[0059] The term "transglutaminase" (Tgase EC 2.3.2.13) refers to an enzyme capable of catalyzing acyl transfer reactions in which the γ-carboxy-amide group of a peptide-bound glutamine group is the acyl donor. In various compounds, primary amino groups function as acyl acceptors, and monosubstituted γ-amides of peptide-bound glutamine are subsequently formed. When the ε-amino group of a lysine residue in a peptide chain serves as an acyl acceptor, Tgase forms intra- or intermolecular γ-glutamyl-ε-lysyl crosslinks. The catalysis proceeds via deamination of glutamine and formation of a protein-glutamyl-thioester at the active site of the enzyme. Nucleophilic attack by the lysyl ε-amino group of a second protein at the carbonyl moiety of the thioester intermediate generates an isopeptide crosslinked protein that is largely resistant to proteolysis by common peptidases (Mariniello, et al. (2007) J Agr Food Chem. 55:4717-4721).
[0060] The bonds formed by Tgase are highly resistant to proteolytic breakdown (proteolysis). Tgase of microbial origin are calcium independent, which is a major advantage for their practical use. Tgase has found many applications in the biotechnology and food processing industries, earning it the name "meat glue". Peptide cross-linking activity has been shown to be useful for a variety of industrial purposes ranging from food processing, biotechnology, pharmaceuticals, medical devices, personal and household products, and leather and textile processing. The most commonly used Tgase is the microbial transglutaminase from Streptomyces mobaraensis, having the amino acid sequence shown in SEQ ID NO: 1, hereinafter referred to as Tgase.
[0061] The term "UV filter" refers to any compound, mixture, substance, or material that blocks, reflects, or absorbs UV light.
[0062] The term "UV light" refers to a form of electromagnetic radiation with wavelengths between 10nm and 400nm, which is in the range of the electromagnetic spectrum between visible light and X-rays. There are three types or bands of UV light: UVA, UVB, and UVC. UVA has a wavelength in the range of 320-400nm. It is not absorbed by the ozone layer. UVA rays are further classified into UVA1 and UVA2. UVA1 has a wavelength between 340-400nm, and UVA2 has a wavelength between 320-340nm. UVB has a wavelength in the range of 290-320nm. It is mostly absorbed by the ozone layer, but some does reach the earth's surface. UVC has a wavelength in the range of 100-290nm. It is completely absorbed by the ozone layer and the earth's atmosphere.
[0063] Related (and derivative) proteins include within their scope "variant" or "mutant" proteins, and these terms are used interchangeably herein. Variant proteins differ from another (i.e., parent) protein and / or from each other by a small number of amino acid residues. A variant may contain one or more amino acid mutations (e.g., amino acid deletions, insertions, or substitutions) compared to the parent protein from which it is derived. Alternatively, or in addition, a variant may have a specified degree of sequence identity with a reference protein or nucleic acid, as determined using sequence alignment tools such as BLAST, ALIGN, and CLUSTAL. For example, a variant protein or nucleic acid can have at least about 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or even 99.5% amino acid sequence identity to a reference sequence, and integer percentages therebetween.
[0064] The term "visible light" refers to the form of electromagnetic radiation perceived by the human eye with wavelengths between 400 nm and 700 nm, which is in the range of the electromagnetic spectrum between UV and infrared light. Among visible light, high-energy visible light (HEVL), with wavelengths between 400 nm and 450 nm, is of particular importance as it induces oxidative stress, free radical generation, and dermal cell damage to the skin.
[0065] The term "visible light filter" refers to any compound, mixture, substance, or material that blocks, reflects, or absorbs UV light.
[0066] The term "wild type" with respect to an amino acid sequence or a nucleic acid sequence indicates that the amino acid sequence or the nucleic acid sequence is a native or naturally occurring sequence. As used herein, the term "naturally occurring" refers to anything that is found in nature (e.g., a protein, amino acid, or nucleic acid sequence). Conversely, the term "non-naturally occurring" refers to anything that is not found in nature (e.g., recombinant / engineered nucleic acid and protein sequences made in the laboratory, or modifications of a wild type sequence).
[0067] As discussed above, UV filters, also called sunscreens or sunblocks, are elements present in photoprotection formulations that directly interfere with the incoming solar radiation through absorption, reflection or scattering of energy. They are divided into two categories based on their mechanism of action: chemical or organic sunscreens, and mineral-based or organic sunscreens.
[0068] In the United States, sunscreen products are classified as over-the-counter (OTC) drugs. This means that they are closely regulated and require pre-market registration by the U.S. Food and Drug Administration (FDA). Regulations regarding sunscreens include the Sunscreen Drug Products for Over-The-Counter Human Use Monograph (21 CFR 352) and the Sunscreen Innovation Act. In February 2019, the U.S. FDA announced a proposed rule to change regulations related to the manufacture and sale of sunscreens and other suncare-related products. The proposed rule aims to update OTC sunscreens, which are non-prescription drugs sold over the counter without FDA approval, along with the latest science to better ensure that consumers have access to safe and effective preventative suncare options.
[0069] Of the 16 sunscreen actives currently on the market, two ingredients, zinc oxide and titanium dioxide, are GRASE (Generally Recognized as Safe and Effective) for use in sunscreens. Two ingredients, para-aminobenzoic acid (PABA) and trolamine salicylate, were considered not GRASE for use in sunscreens. The remaining 12 ingredients, cinoxate, dioxybenzone, ensulizole, homosalate, melazimate, octinoxate, octisalate, octocrylene, padimate O, sulisobenzone, oxybenzone, and avobenzone, were considered to have insufficient safety data to make a positive GRASE determination.
[0070] In contrast, the European Union considers sunscreens to be cosmetics. This classification is so different from that of the United States that some ingredients used in European sunscreens, for example triazine-containing UV filters, are not currently permitted on the U.S. market without oversight. It remains to be seen what will happen with regard to sunscreen development in the United States. Thus, the need for new sunscreen active ingredients continues.
[0071] Disclosed herein is a sunscreen composition comprising at least one ketone-containing UV filter and at least one primary or secondary amine, where the ketone-containing UV filter reacts to form an imine analog of the ketone-containing UV filter, said imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection into the visible range at or above 400 nm, b) being water resistant, and / or c) preventing or reducing skin penetration.
[0072] Thus, disclosed herein is a sunscreen composition comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter reacts to form an imine analog of the ketone-containing UV filter, said imine analog having at least one property selected from the group consisting of: a) usable as a UV filter and a visible light filter; b) being water resistant; and / or c) preventing or reducing skin penetration.
[0073] This is achieved without the need to add another component (e.g., iron oxide pigment) to provide a visible light filter function, which can avoid the drawbacks associated with visible light filters, and fewer active ingredients come into contact with the skin, potentially minimizing the risk of allergic reactions and / or skin irritation. Furthermore, the sunscreen compositions described herein can be manufactured more easily, preferably at lower cost, than multi-component systems. Furthermore, in contrast to using two components as UV filters and visible light filters, each with its own absorption profile, the sunscreen compositions disclosed herein provide continuous photoprotection across the UV to visible light range. Thus, possible wavelength range gaps and / or variations in the degree of protection resulting from the (potentially incomplete) overlap of absorption profiles between the UV filter component and the visible light filter component are avoided. In embodiments of the sunscreen compositions described herein, such sunscreen compositions are free or substantially free of other visible light filters. For example, free or substantially free of pigments such as iron oxides.
[0074] The visible light filters of the sunscreen compositions described herein preferably block or absorb visible light in the wavelength range of 400 nm to 450 nm.
[0075] Examples of ketone-containing UV filters include, but are not limited to, avobenzone, oxybenzone, sulisobenzone, enzacamene, diethylamino hydroxybenzoyl hexyl benzoate, and ecamsul.Preferred ketone-containing UV filters are avobenzone, diethylamino hydroxybenzoyl hexyl benzoate (DHHB), sulisobenzone, and oxybenzone.Most amines that can react with ketone-containing UV filters to produce desired imine analogues are expected to be useful, provided that the imine analogues also have at least one property selected from the group consisting of: a) can extend light absorbance to UVA-1, UVA-2, and / or UVB regions, and 400nm or more visible regions; b) are water-resistant; and / or c) prevent or reduce skin penetration. Examples of such useful amines include, but are not limited to, amino acids, cadaverine, putrescine, hydrazine, adipic dihydrazide, sebacic dihydrazide, ethylenediamine, hexamethylenediamine, benzylamine, aniline, amodimethicone, tromethamine, polyethyleneimine, polylysine, dimethylaminopropylamine, aminomethylpropanol, and the like.
[0076] When at least one ketone-containing UV filter and at least one primary or secondary amine are added to the reactor, they can react to form an imine analog of the ketone-containing UV filter. Preferably, the imine analog is selected from one or more of imine-1, imine-2, imine-4, imine-5, imine-6, imine-7, imine-8, imine-9, N-Boc-imine-7, N-Boc-imine-8, N-Boc-imine-9, and / or imine-10, which are shown in FIG. 8 with their estimated logP values calculated by ChemDraw. In some cases, the resulting imine analog can dimerize, for example, dimer-imine-6, as shown in FIG. 8. In another aspect, the resulting imine analog can be considered as the reaction product of the ketone-containing UV filter and the primary or secondary amine. The imine analog of this embodiment functions simultaneously as a UV filter and a visible light filter, and / or is water-resistant, and / or reduces skin penetration.
[0077] Surprisingly and unexpectedly, this imine analogue formulation of ketone-containing UV filters has at least one property selected from the group consisting of: a) can extend light absorption to UVA-1, UVA-2, and / or UVB regions and 400nm or higher visible region; b) is water-resistant; and / or c) prevents or reduces skin penetration.This is believed to be the first imine-containing sunscreen composition or sunscreen ingredient that has at least one of these properties discussed herein.This is shown in more detail in the following examples and figures provided herein.
[0078] In a further embodiment there is the use of a sunscreen composition as disclosed herein comprising as a visible light filter an imine analogue of a ketone-containing UV filter, said imine analogue being the reaction product of a ketone-containing UV filter with a primary or secondary amine.
[0079] Chemical UV filters are required to remain on the surface of the skin, for example, to maintain their photoprotective properties. Skin penetration of UV filters in sunscreen products should be avoided. In addition to reduced UV protection due to skin penetration, photosensitivity reactions may also occur.
[0080] Successful topical delivery depends on the ability to overcome biological barriers such as the skin. With regard to sunscreen safety, the objective is to limit the skin penetration of chemicals from topical formulations to avoid toxicity. The 500 Dalton rule assumes that the molecular weight (MW) of a compound should be less than 500 Daltons to allow skin absorption (Bos et al., Exp Dermatol 2000: 9:165-169). Therefore, based on this rule, the UV filters in sunscreen compositions should have a MW of at least 500 Daltons to reduce the possibility of skin penetration.
[0081] In addition to MW, another value that is useful in assessing whether a substance will be absorbed by plant, animal, human or other living tissues, or whether it will be easily carried away and spread by water, is the Log P value. This is an important molecular physical property that affects a wide range of systems. The partition coefficient (P) is the ratio of the concentrations of a compound in a mixture of two immiscible solvents at equilibrium. This ratio is therefore a comparison of the solubility of a solute, especially the solubility of a non-ionized solute, in these two liquids. When one of the solvents is water and the other is a non-polar solvent, the Log P value is a measure of lipophilicity or hydrophobicity. Lipophilicity is an important determinant of permeability through tissue membranes. A negative value of Log P means that the compound has a higher affinity for the aqueous phase, i.e., it is more hydrophilic. A positive value of Log P indicates a higher concentration in the lipid phase, i.e., the compound is more lipophilic.
[0082] It is generally believed that small, moderately lipophilic molecules with a MW of less than 500 Daltons and a Log P of 1-3 are expected to penetrate the skin very well. With this in mind, moderately lipophilic molecules with a Log P in the range of 4-6 are believed to be suitable for use as UV filters in sunscreens.
[0083] The terms "water-resistant" or "very water-resistant" replace the term "waterproof" with respect to sunscreen compositions. The terms "water-resistant" or "very water-resistant" may be used when the sun protection provided by a sunscreen product is reduced by less than 50% after a lukewarm bath lasting 40 minutes or 80 minutes, respectively. Once the sunscreen "sticks" to the skin, it is less likely to be washed off in water or when engaging in vigorous sweat-inducing exercise.
[0084] As mentioned above, oxybenzone is a ketone-containing filter that can form its imine analogue by contacting it with a primary or secondary amine. It is also possible to combine two equivalents of oxybenzone or a similar ketone-containing compound with one equivalent of a diamine, such as hexamethylenediamine, to dimerize the oxybenzone via the imine. This is depicted in Figure 8. The resulting dimer has a MW of over 500 Daltons and a Log P above the 1-3 range, while retaining all the benefits provided by extending the range of UV protection into the visible range at or beyond 400 nm.
[0085] In addition to the UV filters described herein, the sunscreen compositions of the present embodiments suitably contain water, emulsifiers, humectants, emollients, thickeners, preservatives, chelating agents, and / or other conventional ingredients in suitable amounts. Preferably, the sunscreen compositions contain 1.0-20% w / w% of the UV filters described herein.
[0086] In another embodiment, the imine analogues of the ketone-containing UV filters disclosed herein may be further modified to react with transglutaminase or any variant thereof and / or lysyl oxidase to provide a substrate capable of binding the sunscreen composition or sunscreen active to a target of interest.
[0087] Ca 2+ There exists a variant of the Tgase enzyme from Streptomyces mobaraensis, an independent microbial transglutaminase (Tgase). The wild-type enzyme from Streptomyces mobaraensis corresponds to the amino acid sequence set forth in SEQ ID NO:1.
[0088] The Tgase variant of SEQ ID NO:1 can be obtained by mutating one or more amino acids in the polypeptide sequence of wild-type Tgase and observing the transglutaminase transamidation activity between glutamine amino acid residues and amine (or hydroxylamine) acceptors.Methods for recombinant expression of proteins with mutant substitutions have been described previously and are well known in the art, including, for example, Molecular Cloning, A Laboratory Manual 4th ed., Cold Spring Harbor Press (1989), Current Protocols in Molecular Biology, John Wiley & Sons (1987-1997).Combinations of point mutations can be generated using several methods, including error-prone PCR, gene shuffling, molecular breeding, etc.
[0089] Tgase variants and wild-type Tgase may further comprise a polyhistidine peptide extension at their C-terminus, as exemplified by amino acid residues 334-339 of SEQ ID NO: 8. The polyhistidine peptide is a useful tag for purification purposes and does not affect enzyme activity. Typically, the polyhistidine peptide is 6-8 residues in length (SEQ ID NO: 9).
[0090] The Tgase variant may further comprise a methionine residue at its N-terminus. The mature wild-type Streptomyces mobaraensis Tgase enzyme lacks the N-terminal methionine residue encoded by the gene sequence encoding the enzyme. In some embodiments, the Tgase variant is expressed as a variant of the mature Streptomyces mobaraensis Tgase that does not have an N-terminal methionine residue. In other embodiments, the Tgase is expressed as a mature Tgase with an additional N-terminal methionine residue that may be provided by the expression vector in which the Tgase is expressed. The Tgase variant of interest may be found in the amino acid sequence of SEQ ID NO: 2, 3, 4, 5, 6 or 7.
[0091] As mentioned above, "target of interest" refers to any exogenous protein or peptide, such as a dermatologically relevant protein, or any part of human or animal body, suitable for binding to imine or enamine form of any ketone-containing UV filter modified to function as substrate for Tgase or any variant thereof.Tgase or any variant thereof then catalyzes the reaction of modified imine or enamine being conjugated / bound to relevant part of human body, i.e., target of interest.For example, target of interest can include, but is not limited to, glutamine-glycine, collagen, keratin and / or elastin.
[0092] Also included in the scope of the present disclosure is a cosmetic or pharmaceutical preparation that comprises any of the sunscreen compositions or sunscreen active ingredients disclosed herein together with a cosmetically or pharma- ceutical acceptable carrier.For example, any of the imine analogues of ketone-containing UV filters disclosed herein may or may not be further modified to react with transglutaminase or any variant thereof and / or lysyl oxidase to provide a substrate that can bind the sunscreen composition or sunscreen active ingredient to a target of interest.
[0093] Suitable cosmetically and pharma- ceutically acceptable carriers are well known in the art.Examples of cosmetically acceptable carriers include, but are not limited to, water and / or water-soluble solvents, aqueous gels, alcoholic gels, ointments, oils, alcoholic or aqueous fluids, water-in-oil emulsions, water-in-silicone emulsions, etc.Non-limiting examples of cosmetically acceptable carriers include glycerin, C1-4 alcohols, organic solvents, fatty alcohols, fatty ethers, fatty esters, polyols, glycols, vegetable oils, mineral oils, liposomes, lamellar lipid materials.
[0094] Examples of organic solvents include, but are not limited to, monoalcohols and polyols, such as ethyl alcohol, isopropyl alcohol, propyl alcohol, benzyl alcohol, and phenylethyl alcohol, or glycols or glycol ethers, such as monomethyl, monoethyl, and monobutyl ethers, or ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, dipropylene glycol, and alkyl ethers of diethylene glycol, such as monoethyl ether or monobutyl ether of diethylene glycol.Other suitable examples of organic solvents are ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, propanediol, and glycerin.The organic solvent can be a volatile or non-volatile compound.
[0095] In some cases, the cosmetically acceptable carrier may comprise water, a mixture of water and at least one cosmetically acceptable organic solvent, or at least one cosmetically acceptable organic solvent.In addition, the cosmetically acceptable carrier may be or comprise ethanol, glycol ether, such as dipropylene glycol n-butyl ether, isodecane, mineral oil, propylene glycol, pentylene glycol, hexylene glycol, glycerol, and mixtures thereof.
[0096] A pharmaceutical carrier or drug carrier is any substance used in the process of drug delivery that serves to improve the selectivity, efficacy, and / or safety of drug administration. Drug carriers can be used to control the release of drugs into the systemic circulation.
[0097] Examples of pharma- ceutically acceptable carriers include, but are not limited to, creams, emulsions, gels, liposomes, nanoparticles, microspheres, polymeric micelles, nanofibers, protein-drug complexes, and / or ointments.
[0098] Non-limiting embodiments of the above disclosed herein: 1. A sunscreen composition comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter and the at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter, said imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection into the visible range at or above 400 nm, b) being water resistant, and / or c) preventing or reducing skin penetration. 2. The sunscreen composition of embodiment 1, wherein the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate (DHHB), sulisobenzone, and oxybenzone. 3. The sunscreen composition of embodiment 2, wherein the imine analog form of the ketone-containing UV filter is further modified to react with transglutaminase or any variant thereof and / or lysyl oxidase to provide a substrate capable of binding said sunscreen composition to a target of interest. 4. A sunscreen active comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter and the primary or secondary amine react to form an imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection into the visible range at or above 400 nm, b) being water resistant, and / or c) preventing or reducing skin penetration. 5. The sunscreen active of embodiment 4, wherein the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate, sulisobenzone, and oxybenzone. 6. The sunscreen active of embodiment 4 or 5, wherein the imine analog form of the ketone-containing UV filter is further modified to provide a substrate that can react with transglutaminase or any variant thereof and / or lysyl oxidase to bind said sunscreen active to a target of interest. 7. A cosmetic or pharmaceutical preparation comprising a sunscreen composition according to embodiment 1 or 2 or a sunscreen active ingredient according to embodiment 4 or 5, and a cosmetically or pharma- ceutically acceptable carrier. 8. A cosmetic or pharmaceutical preparation comprising the sunscreen composition according to embodiment 3 or the sunscreen active ingredient according to embodiment 6 and a cosmetically or pharma- ceutically acceptable carrier. EXAMPLES
[0099] Unless otherwise defined herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994), and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide those of ordinary skill in the art with a general dictionary of many of the terms used in conjunction with this disclosure.
[0100] The present disclosure is further defined in the following Examples. It should be understood that these Examples, while indicating certain embodiments, are given by way of illustration only.
[0101] From the above discussion and examples, those skilled in the art can ascertain the essential features of the present disclosure, and can make various changes and modifications to adapt it to various usages and conditions without departing from its spirit and scope.
[0102] [Example 1] Synthesis and analysis of imines of the oxybenzone series, exploring aromaticity a. Synthesis of imine-1
[0103] [ka]
[0104] To a solution of oxybenzone (301 mg, 1.32 mmol, 1 equiv.) and benzylamine (169 mg, 1.58 mmol, 1.2 equiv.) in toluene (3 mL) was added tetraisopropoxytitanium (747 mg, 2.63 mmol, 2 equiv.) at 25° C. The reaction mixture was heated to 80° C. for 12 h and monitored by LCMS. The reaction was quenched by dilution with water (20 mL) and the product was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Mg2SO4 and concentrated. The crude product was triturated with 1-[2-(4-methylphenoxy)ethyl]-2-[(2-phenoxyethyl)sulfanyl]-1H-benzimidazole (METB) (3 mL) at 25° C. for 15 min and filtered. The filter cake was dried under vacuum to give imine-1 (171 mg, 41% yield) as a green solid, as determined by LCMS and 1 Confirmed by H NMR (CDCl3).
[0105] b. Synthesis of imine-2
[0106] [ka]
[0107] To a solution of oxybenzone (300 mg, 1.31 mmol, 1 equiv.) and aniline (147 mg, 1.58 mmol, 1.2 equiv.) in toluene (3 mL) was added tetraisopropoxytitanium (747 mg, 2.63 mmol, 2 equiv.) at 25° C. The reaction mixture was heated to 80° C. for 12 h and monitored by LCMS. The reaction was quenched by dilution in water (20 mL) and the product was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Mg2SO4 and concentrated. The crude product was triturated with METB (3 mL) at 25° C. for 15 min and filtered. The filter cake was dried under vacuum to give imine-2 (75 mg, 18% yield) as a green solid, as determined by LCMS and HPLC. 1 Confirmed by H NMR (CDCl3).
[0108] c. Synthesis of imine-3
[0109] [ka]
[0110] To a solution of oxybenzone (300 mg, 1.31 mmol, 1 equiv.) and hydroxylamine hydrochloride (109 mg, 1.58 mmol, 1.2 equiv.) in toluene (3 mL) was added tetraisopropoxytitanium (747 mg, 2.63 mmol, 2 equiv.) at 25° C. The reaction mixture was heated to 80° C. for 12 h and monitored by LCMS. The reaction was quenched by dilution in water (20 mL) and the product was extracted with EtOAc (30 mL×3). The combined organic layers were washed with brine (30 mL), dried over Mg2SO4 and concentrated. The crude product was purified by reverse-phase HPLC (column: Xtimate C18 150*40mm*10um; mobile phase: [water (NH3H2O+NH4HCO3)-ACN]; B%: 35%-75%, 10 min) to give imine-3 (82 mg, 25% yield) as an off-white solid, as determined by LCMS and NMR (Hz, 100 MHz ... 1 Confirmed by H NMR (CDCl3).
[0111] d.UVA and UVB absorption characteristics Imine-1, imine-2, and imine-3 were synthesized, purified, and isolated (see above). All three compounds were dissolved separately in acetonitrile to a final concentration of 5 mM (Figure 1) or 0.05 mM (Figure 1, inset) and analyzed by UV / Vis (Cary-50 Spectrophotomer). The spectral characteristics were compared to oxybenzone in acetonitrile. The results are shown in Figure 1.
[0112] The formation of a Schiff base changes the UV absorption properties in the UV and visible ranges of the spectrum. Figure 1 shows that the absorption properties of oxybenzone can be modulated by reaction with an amine to form an imine. Hydroxylamine-Schiff base (imine-3) resulted in a loss of UVA blocking and a decrease in UVB blocking, whereas imine-1 and imine-2 improved both UVA-1, UVA-2 and UVB absorption properties.
[0113] [Example 2] Synthesis of Carbamates (U.S. Patent No. 5,490,980)
[0114] [ka]
[0115] US Patent 5490980 proposed a transglutaminase compatible oxybenzone-derived carbamate by functionalizing the phenolic oxygen of oxybenzone with alkyl-diamine. To evaluate the UV filter properties of the proposed carbamate, carbamate-1 was prepared using methods known in the art. However, functionalization with the phenolic oxygen reduced the UV filter properties, resulting in reduced UVA blocking.
[0116] To a solution of oxybenzone (300 mg, 1.31 mmol, 1 equiv.) and 4-(dimethylamino)pyridine (DMAP) (161 mg, 1.31 mmol, 1 equiv.) in dichloromethane (3 mL) was added (4-nitrophenyl)carbonochloridate (265 mg, 1.31 mmol, 1 equiv.) at 25° C. The reaction was stirred at 25° C. for 2 h. N-Boc-1,6-hexanediamine (284 mg, 1.31 mmol, 1 equiv.) and N-ethyldiisopropylamine (170 mg, 1.31 mmol, 1 equiv.) were added and the reaction was stirred at 25° C. for 2 h. The reaction mixture was poured into water (10 mL) and extracted with ethyl acetate (30 mL×3). The combined organic layers were dried over Mg2SO4 and concentrated. The crude product was purified by reverse-phase HPLC (column: Xtimate C18 150*40mm*10μm; mobile phase: [water (HCl)-ACN]; B%: 50%-80%, 10 min) to give carbamate-1 (165mg, 26% yield) as a white solid, which was confirmed by LCMS and 1 Confirmed by H NMR (DMSO). a.UVA and UVB absorption characteristics Carbamate-1, first described in US Patent No. 5,490,980, was synthesized, purified and isolated (see above). Carbamate-1 was dissolved in acetonitrile to a final concentration of 0.05 mM and analyzed by UV / Vis (Cary-50 Spectrophotomer). Spectral properties were compared to oxybenzone in acetonitrile at a final concentration of 0.05 mM. The results in Figure 2 show that carbamate-1 (with functionalization on the phenolic oxygen) resulted in reduced UV filter properties, more specifically, reduced UVA blocking.
[0117] [Example 3] Synthesis and analysis of oxybenzone series imines that are Tgase substrates.
[0118] a. Synthesis of imine-4
[0119] [ka]
[0120] Oxybenzone (300 mg, 1.31 mmol, 1 equiv.) and N α -(tert-Butoxycarbonyl)-Lysine(N α To a solution of N-Boc-lysine-OH) (388 mg, 1.58 mmol, 1.2 equiv.) was added sodium methoxide (394 μL of 5 M, 1.5 equiv.) at 25° C. The reaction mixture was heated to 80° C. for 12 h and monitored by LCMS. The reaction mixture was quenched by diluting with water (20 mL) and extracted with ethyl acetate (30 mL×2). The organic layer was discarded. The aqueous phase was lyophilized to give the crude product, which was purified by reversed-phase HPLC (column: Xtimate C18 150*40 mm*10 μm; mobile phase: [water(HCl)-ACN]; B%: 30%-60%, 10 min). N-Boc-imine-4 (350 mg, 537 μmol, 41% yield) was isolated as a green solid and was identified by LCMS and HPLC. 1 Confirmed by H NMR (CDCl3).
[0121] To a solution of N-Boc-imine-4 (350 mg, 767 μmol, 1 equiv.) in DCM (10 mL) was added HCl / dioxane (1.15 mL of 4 M, 6 equiv.) at 25° C. The reaction mixture was stirred at 25° C. for 2 h and monitored by LCMS. The reaction mixture was concentrated under vacuum to give the crude product. The crude product was triturated with ethyl acetate (5 mL) at 25° C. for 30 min and filtered. The filter cake was dried under vacuum to give imine-4 (139 mg, 46% yield) as a yellow solid, as determined by LCMS and HPLC. 1 Confirmed by H NMR (DMSO).
[0122] b. Synthesis of imine-5
[0123] [ka]
[0124] To a solution of oxybenzone (500 mg, 2.19 mmol, 1 eq.) and glutamine (384 mg, 2.63 mmol, 1.2 eq.) in methanol (5 mL) was added sodium methoxide (876 μL of 5M, 2 eq.) at 25° C. The reaction mixture was heated to 65° C. for 12 h and monitored by LCMS, which revealed that about 43% of the desired product was formed. The suspension was filtered and the filter cake was washed with methanol (5 mL×3). The combined filtrate was concentrated. The crude product was purified by preparative HPLC and further by SFC (column: DAICEL CHIRALPAK AD (250 mm*30 mm, 10 μm) to give imine-5 (19 mg, 2% yield) as a grey solid, as determined by LCMS and HPLC. 1 Confirmed by H NMR (DMSO).
[0125] c. Synthesis of imine-6
[0126] [ka]
[0127] To a solution of oxybenzone (341 mg, 1.58 mmol, 1.2 equiv) and N-Boc-1,6-hexanediamine (300 mg, 1.31 mmol, 1 equiv) in toluene (3 mL) was added tetraisopropoxytitanium (747.14 mg, 2.63 mmol, 775.84 μL, 2 equiv) at 25 °C. The reaction mixture was heated to 80 °C for 12 h and monitored by LCMS. The reaction was quenched by dilution with water (20 mL) and the product was extracted with EtOAc (30 mL × 3). The combined organic layers were dried over Mg2SO4 and concentrated. The residue was purified by column chromatography (SiO2, ethyl acetate:petroleum ether = 0-30%) to give N-Boc-imine-6 (450 mg, 80% yield) as a yellow oil, confirmed by LCMS.
[0128] [ka]
[0129] To a solution of N-Boc-imine-6 (450 mg, 1.05 mmol, 1 equiv) in dichloromethane (10 mL) was added HCl / dioxane (4 M, 1.32 mL, 5 equiv). The reaction was stirred at 25° C. for 2 h and monitored by LCMS. The reaction was concentrated under vacuum to give target 6 (95 mg, 27% yield) as a green oil, as determined by LCMS and NMR (Hz) . 1 Confirmed by H NMR (DMSO).
[0130] d.UVA and UVB absorption characteristics Imine-4, imine-5, and N-Boc-imine-6 were synthesized, purified, and isolated (see above). All three compounds were dissolved separately in acetonitrile to a final concentration of 5 mM (Figure 3) and analyzed by UV / Vis (Cary-50 Spectrophotomer). N-Boc-imine-6 was diluted in acetonitrile to a final concentration of 0.05 mM (Figure 3, inset) and analyzed by UV / Vis. Due to its poor solubility in acetonitrile, N-Boc-imine-6 was utilized instead of imine-6 for this data. The spectral characteristics were compared to oxybenzone at the same concentration in acetonitrile. Figure 3 depicts the absorption spectra of the three imines derived from oxybenzone, showing that the three imines cover the UVA-1, UVA-2, and UVB regions as well as the visible region of the spectrum (above 400 nm).
[0131] To understand the solution stability of Boc-protected imines in protic solvents, N-Boc-imine-6 was prepared in ethanol in the presence of catalytic glacial acetic acid. Briefly, to a solution of oxybenzone (0.10 g, 0.438 mmol, 1 equiv.) and N-Boc-1,6-hexanediamine (0.094 g, 0.43 mmol, 1 equiv.) in ethanol (0.3 mL), catalytic glacial acetic acid (1 μL) was added. The reaction mixture was stirred at 900 rpm at 70 °C for 16 h and monitored by LCMS. Complete reaction of the starting material to a single product peak was observed by LCMS, indicating completion. The reaction was subsequently diluted in ethanol to a final concentration of 0.04 mM and analyzed by UV / Vis spectroscopy. N-Boc-imine-6 was stable in ethanol at elevated temperature (70 °C) for 24 h without reversion to the starting ketone and amine (Figure 4). Furthermore, the Boc protecting group remained intact throughout the reaction and UV / Vis analysis. The results in Figure 4 show that the absorption of N-Boc-imine 6 covers the UVA and UVB regions as well as the visible region of the spectrum (above 400 nm).
[0132] [Example 4] Synthesis and analysis of avobenzone imine, imine-7
[0133] [ka]
[0134] To a solution of avobenzone (2 g, 6.44 mmol, 1 equiv.) and N-Boc-1,6-hexanediamine (1.39 g, 6.44 mmol, 1 equiv.) in toluene (80 mL) was added 4A molecular sieves (2 g, 9.90 mmol, 1.54 equiv.) followed by Amberlyst® 15 hydrogen form (2 g, 6.37 mmol) under N2 at 25°C. After addition, the reaction mixture was stirred at 110°C for 72 h and monitored by LCMS. The suspension was filtered and the filter cake was washed with DCM (20 mL x 3). The combined filtrate was concentrated. The residue was purified by column chromatography (SiO2, ethyl acetate:petroleum ether = 0-25%). N-Boc-imine-7 (1.09 g, 1.99 mmol, approx. 30% yield) was obtained as a yellow oil and was confirmed by LCMS and 1H NMR (CDCl3).
[0135] To a solution of N-Boc-imine-7 (300 mg, 590 μmol, 1 equiv) in DCM (6 mL) was added HCl / dioxane (4 M, 737 μL, 5 equiv) at 25° C. under N2. After addition, the reaction mixture was stirred at 25° C. for 4 h and monitored by LCMS. The mixture was concentrated to dryness to give imine-7 (150 mg, 332 μmol, approx. 50% yield) as a yellow oil according to LCMS and 1 Confirmed by H NMR (DMSO).
[0136] UVA and UVB Absorption Characteristics Imine-7 and N-Boc-imine-7 were synthesized, purified, and isolated using preparative HPLC (see above). Imine-7 and N-Boc-imine-7 were dissolved in acetonitrile to an estimated concentration of 5 mM (Figure 5) and 0.05 mM (Figure 5, inset). Both solutions were analyzed by UV / Vis (Cary-50 Spectrophotomer). The concentration of imine-7 and N-Boc-imine-7 (0.05 mM) is an estimate and the absorbance signal is lower than expected. The lower purity of the compounds is likely due to the presence of added salts and residual t-butanol from the HPLC purification (confirmed by NMR). Spectral characteristics were compared to avobenzone in acetonitrile for qualitative purposes only, as the extinction coefficients are likely to be equal to or greater than non-functionalized avobenzone. The results are shown in Figure 5.
[0137] [Example 5] Synthesis and analysis of sulisobenzone-derived imines, Tgase substrates.
[0138] [ka]
[0139] To a solution of sulisobenzone (0.10 g, 0.32 mmol, 1 equiv.) and N-Boc-1,6-hexanediamine (0.070 g, 0.32 mmol, 1 equiv.) in ethanol (0.3 mL) was added catalytic glacial acetic acid (1 μL). After addition, the reaction mixture was stirred at 70° C. for 16 h and monitored by LCMS. N-Boc-imine-8 was concentrated and used without further purification. LCMS showed a single peak with m / z of 506, 407, and 432.
[0140] N-Boc-imine-8 (0.32 μmol, 1 equiv.) in DCM (6 mL) is treated with HCl / dioxane (4 M, 737 μL, 5 equiv.) for 4 h at 25° C. The mixture is concentrated to give imine-8.
[0141] Alternatively, imine-8 was prepared directly by reaction of sulisobenzone (1 equiv.) with 1-6-hexamethylenediamine (1 equiv.) in refluxing ethanol.
[0142] UVA and UVB Absorption Characteristics N-Boc-imine-8 and imine-8 were synthesized, purified and isolated (see above). N-Boc-imine-8 and imine-8 were dissolved in ethanol to a final concentration of 0.032 mM and 8 mM, respectively (Figure 6) and analyzed by UV / Vis (Cary-50 Spectrophotomer). The spectral characteristics were compared with sulisobenzone in ethanol at a similar concentration. The results in Figure 6 show that N-Boc-imine-8 and imine-8 maintained absorbance in the UVB region and extended absorbance into the UVA region.
[0143] [Example 6] Synthesis and analysis of diethylaminohydroxybenzoylhexylbenzoate-derived imines, Tgase substrates.
[0144] [ka]
[0145] To a solution of diethylamino hydroxybenzoyl hexyl benzoate (DHHB) (0.10 g, 0.25 mmol, 1 equiv.) and N-Boc-1,6-hexanediamine (0.070 g, 0.32 mmol, 1 equiv.) in toluene (0.3 mL) was added catalytic glacial acetic acid (1 μL). After addition, the reaction mixture was stirred at 95° C. for 16 h and monitored by LCMS. The reaction was concentrated and used without further purification to give a deep orange oil. LCMS showed a single peak with m / z of 595 and 495.
[0146] N-Boc-imine-9 (0.32 μmol, 1 equiv.) in DCM (6 mL) is treated with HCl / dioxane (4 M, 737 μL, 5 equiv.) at 25° C. for 4 h. The mixture is concentrated to give imine-9. Alternatively, imine-9 was prepared directly by reaction of DHHB (1 equiv.) with 1-6-hexamethylenediamine (1 equiv.) in refluxing ethanol. Both N-Boc-imine-9 and imine-9 result in a red shift in the absorbance spectrum, which extends into the visible region (data not shown).
[0147] [Example 7] Synthesis and analysis of oxybenzonimine on high molecular weight polymers.
[0148] [ka]
[0149] To oxybenzone (100.0 mg, 0.44 mmol, 1 equiv.) was added amodimethicone (910.0 mg, 0.55 mmol, 1.2 equiv.) at 25° C. The reaction mixture was heated to 95° C. for 16 hours with continuous mixing. Upon heating, the oxybenzone melted and formed an immiscible phase at the bottom of the vial. As the reaction proceeded, the oxybenzone phase contracted and the amodimethicone phase became clear yellow. Imine-10 was obtained by continuing the reaction in the vial until a single clear yellow phase was formed. The high molecular weight imine polymer described in this example has increased absorbance in the UVA range as well as the visible range (FIG. 7) and avoids skin penetration due to its high molecular weight. Imine-10 is believed to be water resistant due to the hydrophobicity of the silicone backbone.
[0150] UVA and UVB Absorption Characteristics Imine-10 was first dissolved in methyl tert-butyl ether and subsequently diluted in ethanol to final concentrations of 5 mM and 0.04 mM (Figure 7) and analyzed by UV / Vis (Cary-50 Spectrophotomer). The spectral characteristics were compared with oxybenzone at similar concentrations. The results in Figure 7 show that imine-10 retained absorbance in the UVB region and extended absorbance into the UVA and visible regions.
[0151] [Example 8] Covalent attachment of sunscreen linkers to peptides
[0152] [ka]
[0153] Cbz-Gln-Gly dipeptide (100 μL of a 10 g / L stock solution dissolved in 90% aqueous acetonitrile) was added to a solution of wild-type transglutaminase or variants (SEQ ID NOs: 2 and 7) in 0.1 M Tris-HCl pH 8.0, 1 mM EDTA (800 μg / L, final concentration 0.03 g / L). To this solution was added the imine product described in Examples 3-6 (100 μL of a 10 g / L stock solution dissolved in the solvent specified in Table 2) dissolved in a suitable solvent. The suspension was incubated overnight at 37° C. with constant stirring. The covalent addition of the dipeptide to the imine catalyzed by transglutaminase (wild-type or variant) was confirmed by HPLC and LCMS. The conversion of the starting material to the product was calculated using the peak areas. The relative reactivity is calculated by dividing the total conversion by the data obtained for the least reactive imine. In the absence of transglutaminase, no covalent addition of imines to peptides was observed. The reactivity of the imines depended on the solubility of the imines upon addition to the aqueous reaction. More water-soluble imines lead to higher conversion to imine-peptide products.
[0154] [Table 2]
[0155] [Example 9] Sunscreen composition formulation Sunscreen compositions containing any of the UV filters described herein can be formulated as described in Table 3. The formulations described below are suitable for both oil-in-water and water-in-oil emulsions.
[0156] [Table 3]
[0157] [Example 10] Determining the water resistance of sunscreens In vitro test method (based on the method of Markovic et al, Alured's Cosmetics and Toiletries, 116(9):61-28 (2001)) Prior to application of the sunscreen, large strips (20 x 10 cm) of Vitro-Skin® N-19 (IMS, Inc.) are hydrated according to the manufacturer's recommendations (16-18 hours at room temperature and 90-95% relative humidity). Vitro-Skin® mimics the composition, wettability, pH, ionic strength, and surface topography properties of human skin. A measured amount (6-7 mg) of a formulation containing an imine or enamine as described herein is applied onto a pre-hydrated strip of Vitro-Skin® (28 x 38 mm) mounted on a 35 mm slide mount. The emulsion is carefully spread using a rubber-gloved finger, first with a circular motion followed by a linear motion for approximately 1 minute. The sample is then placed in a humidified chamber (90-95% relative humidity at room temperature) for 20 minutes to allow the emulsion to coalesce. Using a spectrophotometer, collect four UV spectra per sample in the wavelength range of 250-350 nm. Each spectrum is collected after rotating the sample by 90°, resulting in four separate area scans for each sample. The samples are scanned against an untreated reference sample in the reference beam of a two-beam spectrophotometer. Absorption readings are taken at 310 and 291 nm and are named as the initial absorbance Ai. The samples are subsequently immersed in a temperature-controlled water bath (25 ± 0.2 °C) for 80 min with constant mixing at 50 rpm using a paddle-type impeller. The volume of the water bath is large enough (2000 ml) to prevent high concentration of the dispersed sunscreen and possible re-adsorption. After immersion, the samples are removed from the water, gently shaken to remove large water droplets, and hung in room air adjusted to a relative humidity of 50% for 30 min. The samples are then placed back in the humidity chamber for 120 min. A final absorbance reading, Af, is obtained in the same way as the first. The percentage of water resistance is calculated as (Af / Al) x 100. Samples are evaluated in quadruplicate to obtain 32 readings (4 samples x 4 directions x 2 wavelengths) for each formulation tested. It is important that the samples remain hydrated; if the sample loses too much water, the Vitro-Skin® becomes opaque and unsuitable for spectrophotometric analysis. Each blank control sample (without sunscreen) is treated and measured in exactly the same way.The control samples are immersed in a separate water bath to avoid migration of sunscreen from the formulation-treated samples.
[0158] [Example 11] Construction and mutagenesis of Tgase vector Cell-free protein synthesis (CFPS) vectors The gene encoding the prosequence and mature Tgase was codon-optimized for expression in Escherichia coli (E. coli) based on the published amino acid sequence (Kanaji, et al. (1993) J. Biol. Chem. 268(16):11565-11572), synthesized, and cloned onto a pUC19-derived expression vector, as described in PCT / US20 / 49226.
[0159] E. coli vectors The gene encoding the prosequence and mature Tgase was codon-optimized and synthesized for expression in E. coli based on the published amino acid sequence (Kanaji, et al. (1993) J. Biol. Chem. 268(16):11565-11572) as described in PCT / US20 / 49226. The DNA was cloned into the pET9a vector under the control of the T7 promoter for expression in E. coli.
[0160] Generation of Tgase variants Mutations were introduced into the mature Tgase gene using site-directed mutagenesis techniques known in the art.
[0161] [Example 12] Expression of Tgase variants using cell-free protein synthesis The prosequence and mature Tgase variants were co-expressed in a commercially available cell-free protein synthesis kit according to the manufacturer's instructions, as described in PCT / US20 / 49226.
[0162] [Example 13] Expression and purification of Tgase variants in Escherichia coli E. coli BL21(DE3) cells harboring the Tgase expression plasmid were grown in shake flasks, lysed by homogenization, and Tgase was isolated from cell debris by centrifugation. The resulting semi-purified enzyme (clarified lysate) was further purified by affinity column on Ni-IMAC resin before dialysis. Purified Tgase was stored at -80°C.
[0163] [Example 14] Measurement of Tgase specific activity In the examples herein, a colorimetric hydroxamate activity assay (Folk and Cole (1965) J Biol Chemistry 240(7):2951-2960) was used to measure Tgase specific activity. Briefly, the hydroxamate assay uses N-carbobenzoxy-L-glutamylglycine (Z-Gln-Gly or CBZ-Gln-Gly) as the amine acceptor substrate and hydroxylamine as the amine donor. In the presence of transglutaminase, hydroxylamine is incorporated to form Z-glutamylhydroxamate-glycine, which after incubation at 37°C for 5-60 minutes produces a colored complex with iron(III) detectable at 525 nm. Calibration was performed using L-glutamic acid γ-monohydroxamate (Millipore Sigma) as a standard. One unit of Tgase is defined as the amount of enzyme that catalyzes the formation of 1 μmol of peptidic derivative of γ-glutamylhydroxylamine per minute.
[0164] All publications, patents, and patent applications cited in this specification are herein incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
[0165] [ka]
Claims
1. 1. A sunscreen composition comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein the ketone-containing UV filter and the at least one primary or secondary amine react to form an imine analog of the ketone-containing UV filter, the imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection into the visible range at or above 400 nm; b) being water resistant; and / or c) preventing or reducing skin penetration.
2. 2. The sunscreen composition of claim 1, wherein the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate, sulisobenzone, and oxybenzone.
3. 3. The sunscreen composition according to claim 1 or 2, wherein the imine analogue form of the ketone-containing UV filter is further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and / or lysyl oxidase to bind the sunscreen composition to a target of interest.
4. 1. A sunscreen active comprising at least one ketone-containing UV filter and at least one primary or secondary amine, wherein said ketone-containing UV filter and said primary or secondary amine react to form an imine analog having at least one property selected from the group consisting of: a) capable of extending UV protection into the visible range at or above 400 nm; b) being water resistant; and / or c) preventing or reducing skin penetration.
5. 5. The sunscreen active of claim 4, wherein the ketone-containing UV filter is selected from the group consisting of avobenzone, diethylamino hydroxybenzoyl hexyl benzoate, sulisobenzone, and oxybenzone.
6. 6. A sunscreen active according to claim 4 or 5, wherein the imine analogue form of the ketone-containing UV filter is further modified to provide a substrate capable of reacting with transglutaminase or any variant thereof and / or lysyl oxidase to bind the sunscreen active to a target of interest.
7. 6. A cosmetic or pharmaceutical preparation comprising a sunscreen composition according to claim 1 or 2 or a sunscreen active ingredient according to claim 4 or 5, and a cosmetically or pharma- ceutically acceptable carrier.
8. 10. A cosmetic or pharmaceutical preparation comprising the sunscreen composition of claim 3 or the sunscreen active ingredient of claim 6 and a cosmetically or pharma- ceutically acceptable carrier.
